Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In this Collection Review for the Novel Treatments for Tuberculosis Collection, Piero Olliaro and Michael Vaillant discuss the considerations when choosing a non-inferiority margin that is meaningful from statistical, ethical, clinical, and health standpoint.

Original publication

DOI

10.1371/journal.pmed.1002850

Type

Journal article

Journal

PLoS medicine

Publication Date

12/07/2019

Volume

16

Addresses

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Keywords

Humans, Tuberculosis, Antitubercular Agents, Treatment Outcome, Drug Therapy, Combination, Endpoint Determination, Data Interpretation, Statistical, Models, Statistical, Risk Assessment, Risk Factors, Research Design, Equivalence Trials as Topic